Public Company News
Registrational Phase III CLARIFY trial: Target number of participants achieved
SYDNEY, Oct. 27, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the registration...
2026-10-27 21:02
2697
Webull Canada Introduces AI-Powered Investing That Lets You Trade Using Plain Language
Clients will be able to connect their Webull accounts to popular AI platforms, allowing them to research, review portfolios and place trades directly within the chat interface. TORONTO, Oct. 27, 2026 /PRNewswire/ -- Webull Securities (Canada) Ltd, an online investment platform and subsidiary of ...
2026-10-27 21:00
4097
Massimo Group Reports Strong Dealer Response to New Warrior 1500XD and Sentinel 1500 HVAC Crew Following Equip Exposition Debut
Company Generates More Than 100 Prospective Dealer Leads and Estimates Initial Pre-Order Demand Exceeding 100 Units Ahead of Official SEMA Launch GARLAND, Texas, Oct. 27, 2026 /PRNewswire/ -- Massimo Group (NASDAQ: MAMO) ("Massimo" or the "Company"), a manufacturer and distributor of powersports ...
2026-10-27 21:00
4809
WF Holding Limited Announces Share Consolidation
KUALA LUMPUR, Malaysia, Oct. 27, 2026 /PRNewswire/ -- WF Holding Limited (NASDAQ: WFF) (the "Company"), today announced that it will effect a share consolidation of its ordinary shares, par value $0.00025 per share, at a ratio of 1-for-25, effective on October 30, 2026 (the "Share Consolidation")...
2026-10-27 20:30
2617
Yuchai Strengthens African Continent Coverage
SINGAPORE, Oct. 27, 2026 /PRNewswire/ -- China Yuchai International Limited (NYSE: CYD) ("China Yuchai International" or the "Company"), one of the largest powertrain solution manufacturers through its main operating subsidiary in China, Guangxi Yuchai Machinery Company Limited ("Yuchai"), announ...
2026-10-27 19:41
5370
New Indication Application for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Accepted for Review by NMPA
* This is the seventh indication application for sacituzumab tirumotecan (sac-TMT) and the second application for the ADC plus IO combination regimen of sac-TMT plus pembrolizumab accepted for review. * The Phase III OptiTROP-Lung06 study supporting this application showed that sac-TMT plus p...
2026-10-27 19:10
3499
Daqo New Energy Announces Unaudited Third Quarter 2026 Financial Results
SHANGHAI, Oct. 27, 2026 /PRNewswire/ -- Daqo New Energy Corp. (NYSE: DQ) ("Daqo New Energy," the "Company" or "we"), a leading manufacturer of high-purity polysilicon for the global solar PV industry, today announced its unaudited financial results for the third quarter ended September 30, 2026. ...
2026-10-27 18:00
4320
HUYA Inc. to Report Third Quarter 2026 Financial Results on Tuesday, November 17, 2026
-Earnings Webinar Scheduled for 5:00 a.m. ET on November 17, 2026- GUANGZHOU, China, Oct. 27, 2026 /PRNewswire/ -- HUYA Inc. ("Huya" or the "Company") (NYSE: HUYA), a leading game-related entertainment and services provider, today announced that it will report its third quarter 2026 unaudited fi...
2026-10-27 18:00
2079
Baidu to Report Third Quarter 2026 Financial Results on November 16, 2026
BEIJING, Oct. 27, 2026 /PRNewswire/ -- Baidu, Inc. (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) ("Baidu" or the "Company"), a leading AI company with strong Internet foundation, today announced that it will report its financial results for the Third Quarter 2026 ended Septembe...
2026-10-27 17:00
2266
Big Tree Cloud Holdings Limited Announces Filing of Annual Report on Form 20-F for Fiscal Year 2026
SHENZHEN, China, Oct. 26, 2026 /PRNewswire/ -- Big Tree Cloud Holdings Limited ("Big Tree Cloud" or the "Company") (NASDAQ: DSY; DSYWW), a capital platform focusing on industrial integration and strategic investments in the Chinese personal care industry and a provider of AI technology services,...
2026-10-27 06:00
2049
ROKAE delivers its 10,000th humanoid force-controlled arm
Milestone delivery highlights industrial adoption, with ROKAE robots deployed
at Schaeffler's Lighthouse Factory in China
BEIJING, Oct. 26, 2026 /PRNewswire/ -- ROKAE Robotics
2026-10-27 00:00
16159
FF EAI Robotics Ecosystem Completed its Acquisition of the Robotics Business of Faraday Future, Establish Nasdaq-Listed Humanoid and Bionic Robotics Platform
* FFR expects October 2026 robot sales and shipments to exceed 300 units, setting a new monthly record and bringing cumulative shipments to more than 1,100 units, while continuing to deliver robots at a positive unit gross margin LOS ANGELES, Oct. 26, 2026 /PRNewswire/ -- FF EAI Robotics Ecosys...
2026-10-26 23:30
5986
Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026
CAMBRIDGE, Mass., Oct. 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage generative AI–driven drug discovery company, today announced promising first-in-human Phase 1 data for ISM6331, its investigational oral pan-TEAD inhibitor designed using Chemistry42 gener...
2026-10-26 21:00
4273
WuXi AppTec Delivers Strong Q1-Q3 2026 Results and Further Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers' Products and CRDMO Model
SHANGHAI, Oct. 26, 2026 /PRNewswire/ -- WuXi AppTec (Stock Codes: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first three quarters ending September 30, 2026 ("Reporting Peri...
2026-10-26 17:25
4336
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
SAN FRANCISCO and SUZHOU, China, Oct. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2026-10-26 17:18
2356
111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
SHANGHAI, Oct. 26, 2026 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), comprising three independent directors, Mr. Jian Sun, who is the chairman of...
2026-10-26 16:00
2223
Results of CARsgen's Satri-cel for Adjuvant Treatment for Gastric Cancer Presented at ESMO Congress 2026
SHANGHAI, Oct. 25, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the preliminary positive research results of the investigator-initiated trial (CT041-CG4010, NCT06857786) in China o...
2026-10-26 08:30
5607
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
* The data showcased are from three Phase 1b clinical studies of IBI363/TAK-928 in first-line NSCLC, first-line G/GEJA, and immunotherapy-resistant lung adenocarcinoma, further supporting its potential clinical value across treatment settings. SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PR...
2026-10-26 08:00
3627
2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabol...
2026-10-25 14:00
5133
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabol...
2026-10-25 14:00
4747
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 309 media titles]
2026-10-27 13:40
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 281 media titles]
2026-10-23 21:52
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 276 media titles]
2026-10-28 09:00
Most Read
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
40564
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
40545
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
39300
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
31874